Most-Downgraded StocksMost-DowngradedNASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $245.51 +6.15 (+2.57%) Closing price 09/17/2026 04:00 PM EasternExtended Trading$246.06 +0.55 (+0.22%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ALNY alerts:Sign Up Key Stats Today's Range$239.50▼$245.6350-Day Range$205.48▼$298.7652-Week Range$197.81▼$495.55Volume1.01 million shsAverage Volume1.59 million shsMarket Capitalization$32.85 billionP/E Ratio45.63Dividend YieldN/APrice Target$367.20Consensus RatingModerate Buy Company Overview Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran). These medicines are used to treat rare diseases including hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1. Amvuttra is also approved for certain forms of transthyretin amyloidosis, including disease affecting the heart. The company continues to develop RNAi-based treatments for diseases in areas such as genetic disorders, cardiometabolic conditions, central nervous system diseases and liver-related conditions. Alnylam serves patients and healthcare markets internationally through its commercial operations, regulatory approvals and partnerships with other pharmaceutical companies.AI Generated. May Contain Errors. Read More Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreALNY MarketRank™: Alnylam Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 86th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 2 strong buy ratings, 16 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialAlnylam Pharmaceuticals has a consensus price target of $367.20, representing about 49.6% upside from its current price of $245.51.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth44.56% Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow by 44.56% in the coming year, from $6.71 to $9.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is 45.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is 45.63, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.33.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 41.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.78% of the float of Alnylam Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 32.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment0.70 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 11 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.86% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALNY Stock News HeadlinesRNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics44 minutes ago | finance.yahoo.comAlnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control TranscriptSeptember 17 at 5:00 PM | seekingalpha.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 18 at 1:00 AM | Paradigm Press (Ad)Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism?September 15 at 7:05 PM | finance.yahoo.comAlnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter PictureSeptember 15 at 4:44 AM | fool.comAlnylam Pharmaceuticals, Inc. (ALNY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comHead-To-Head Review: Alnylam Pharmaceuticals (NASDAQ:ALNY) vs. Cellectis (NASDAQ:CLLS)September 10, 2026 | americanbankingnews.comJefferies Financial Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) StockSeptember 10, 2026 | americanbankingnews.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $397.65 at the beginning of the year. Since then, ALNY stock has decreased by 38.3% and is now trading at $245.51. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The company's quarterly revenue was up 66.9% on a year-over-year basis. Read the conference call transcript. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional shareholders include Wellington Management Group LLP (1.58%), Legal & General Group Plc (0.69%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.54%) and Bank of New York Mellon Corp (0.37%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Tolga Tanguler, Pushkal Garg, Kevin Joseph Fitzgerald, Michael W Bonney, Melissa Mclaughlin, Amy W Schulman, David E I Pyott, Dennis A Ausiello, Colleen F Reitan and Phillip A Sharp. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR). Company Calendar Last Earnings7/30/2026Today9/18/2026Investor update10/26/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ALNY's financial health is in the Red zone, according to TradeSmith. ALNY has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,770Year Founded2002Price Target and Rating Average Price Target for Alnylam Pharmaceuticals$367.20 High Price Target$489.00 Low Price Target$256.00 Potential Upside/Downside+49.6%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$5.38 Trailing P/E Ratio45.63 Forward P/E Ratio36.59 P/E GrowthN/ANet Income$313.75 million Net Margins15.26% Pretax Margin15.95% Return on Equity84.93% Return on Assets14.30% Debt Debt-to-Equity Ratio0.75 Current Ratio3.05 Quick Ratio2.99 Sales & Book Value Annual Sales$3.71 billion Price / Sales8.85 Cash Flow$2.87 per share Price / Cash Flow85.61 Book Value$5.97 per share Price / Book41.12Miscellaneous Outstanding Shares133,810,000Free Float132,658,000Market Cap$32.85 billion OptionableOptionable Beta0.31 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ALNY) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts